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ABSTRACT 
Donepezil and Galanin Interactions in an Animal Model of Alzheimer’s Disease 
by 
Jonathan Jacob Sabbagh 
Dr. Jefferson Kinney, Examination Committee Chair 
Assistant Professor of Psychology 
University of Nevada, Las Vegas 
 
 
 Alzheimer’s disease (AD) is a neurodegenerative disorder marked by a 
progressive loss of cognitive function. One of the neurobiological hallmarks of AD is a 
progressive loss of cholinergic neurons and a decrease in the amount of acetylcholine in 
the brain. Pharmacological therapies have targeted the cholinergic system, specifically 
first-line, palliative treatment using acetylcholinesterase (AChE) inhibitors, such as 
donepezil. Donepezil has been shown to increase cholinergic tone and ameliorate some of 
the cognitive deficits in AD patients. Galanin, a neuropeptide that inhibits the evoked 
release of several neurotransmitters including acetylcholine as well as modulates seveal 
intracellular cascades, is overexpressed in AD resulting in an as yet unidentified 
modulation of neurobiological function. Galanin also impairs learning and memory when 
administered centrally to rodents, suggesting it may contribute to the cognitive 
impairments observed in AD. While the mechanism by which galanin impairs learning 
has yet to be determined, studies suggest it is through cholinergic mechanisms. We 
investigated the ability of donepezil to rescue learning and memory deficits induced by 
galanin administration, and by extension isolated whether the learning impairments 
produced by galanin were ameliorated by increasing cholinergic tone. We also 
investigated the effects of donepezil and galanin in an animal model of AD, i.e. their 
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effects on learning and memory following a slight lesion of cholinergic neurons 
analogous to the cholinergic loss seen in AD. This study provides vital information about 
the relationship between galanin-induced deficits and acetylcholine, and helps to clarify 
the roles of donepezil and galanin in AD.  
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CHAPTER 1 
INTRODUCTION 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by a 
progressive loss of memory and a decline in cognitive function (Heese & Akatsu, 2006). 
It is the most common cause of age-related dementia accounting for 50-60% of age-
related cases. The average age of onset for AD is 65 years, while most cases occurring 
before this age are referred to as early-onset familial AD, with identifiable genetic links. 
Other symptoms accompanying the memory loss are confusion, disorientation, anxiety, 
delusions and apathy or depression (Terry & Katzman, 1983). As the disease advances, 
symptoms may include anger, aggression, language problems, and impaired motor 
function (Souren et al., 1995; Waldemar et al., 2007). In addition to the behavioral 
disruptions associated with AD, several pathological changes have been observed in the 
brain including beta-amyloid (Aβ) plaque deposition, neurofibrillary tangle formation, 
and the progressive loss of cholinergic neurons (Bartus et al., 1982; Glenner & Wong, 
1984; Masters et al., 1985; Arriagada et al., 1992; Goedert, 1996). These pathological 
changes are the hallmarks of the disease, and may be responsible for the cognitive and 
behavioral deficits exhibited in AD.  
One of the most extensively investigated hallmarks of the disorder is the senile 
plaques observed in post mortem examinations. Aβ proteins form the core of senile 
plaques, one of the pathological changes which may be inducing the neuronal loss seen in 
AD (Glenner & Wong, 1984; Masters et al., 1985). Senile plaques are extracellular 
structures composed mainly of aggregated Aβ, and they are seen almost exclusively in 
AD and AD-related pathologies like Down syndrome (Wisniewski et al., 1985). Several 
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studies suggest that the accumulation of Aβ in the brain may initiate or lead to the 
pathogenesis of AD (Selkoe, 2001). These findings and others have led to the amyloid 
cascade hypothesis (Hardy & Higgins, 1992), which suggests that the amyloid deposits 
that form plaques are the causative event in AD and the resulting neurodegeneration is a 
by-product of this buildup. Evidence supporting this hypothesis comes from genetic 
studies showing mutations in the genes associated with familial and late-onset AD lead to 
increased Aβ aggregation and cognitive deficits (Goate et al., 1991; Murrell et al., 1991; 
Corder et al., 1993; Levy-Lahad et al., 1995; Sherrington et al., 1995).  
Investigators have been searching for genetic ties to AD for years in an attempt to 
determine the etiology of the disease but with only mild success. Although a few genes 
have been implicated as risk factors, none have yet provided a clear link between the 
pathogenesis of AD and specific genetic targets, with most promising targets tied to 
familial AD. Mutations in the amyloid precursor protein (APP), which is responsible for 
the formation of Aβ peptides and whose encoding gene is located on chromosome 21, 
have been linked to early-onset familial AD (Goate et al., 1991; Murrell et al., 1991). 
Also, patients with Down syndrome, a trisomy (additional copy) of chromosome 21, 
show AD pathology by 40 years of age (Holtzman et al., 1996). Alternative genetic 
approaches have implicated mutations in genes called presenilins (PS) which have also 
been tied to early-onset AD, specifically presenilin-1 (PS-1) and presenilin-2 (PS-2) 
located on chromosomes 14 and 1, respectively (Levy-Lahad et al., 1995; Sherrington et 
al., 1995). In AD, genetic investigations have implicated a specific allele of 
Apolipoprotein E (ApoE), whose gene is localized on chromosome 19, which has been 
linked to an increased likelihood of developing the disease (Corder et al., 1993). 
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Although genetic linkage studies have provided useful insight into potential AD etiology, 
genetic mutations related to Aβ can only account for a small percentage of AD cases. A 
further limitation of the Aβ hypothesis is that many studies have indicated that there is 
little to no correlation between the number or size of amyloid deposits and the severity of 
the dementia, and that other pathologies seem to correlate better with the memory loss 
seen in AD (Terry et al., 1991; Arriagada et al., 1992). Therefore, additional pathologies 
such as the hyperphosphorylation of tau have been the focus of much research. 
Neurofibrillary tangles (NFTs) are another neuropathological hallmark of AD and 
are composed mainly of hyperphosphorylated tau, a protein that is associated with 
microtubule stability and assembly. Tau hyperphosphorylation leads to the formation of 
paired helical filaments (PHF) which are thought to lead to microtubule disintegration 
and neuron death (Goedert, 1996). Because neurofibrillary pathology, as well as the 
number of cortical tangles, correlates positively with the severity of dementia in AD 
(Arriagada et al., 1992), it is of great interest to investigators of the disorder and those 
developing pharmacological treatments. In addition, the regions of the brain that appear 
to undergo the greatest degeneration of neurons and synapses in AD are those that project 
to or from areas that have high densities of plaques and tangles, specifically the 
hippocampus, neocortex, and basal forebrain (for review, see Kar et al., 2004). The latter 
region contains large numbers of cholinergic neurons which project to the hippocampus 
and cortex. Acetylcholine (ACh), principally an excitatory neurotransmitter, is important 
for attentional processes, as well as learning and memory (Deutsch, 1971; Wenk et al., 
1994; Woolf, 1996). A reduction in neurons containing ACh has been consistently 
observed in AD, particularly in the early stages of the disorder.  
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Cholinergic cell loss is a hallmark of the neurodegeneration in AD, marked by a 
progressive loss of ACh-containing neurons with a corresponding decline in cognitive 
function (Perry et al., 1981; Terry et al., 1991). The cholinergic hypothesis of AD 
postulates that the cognitive deficits in AD are caused by the early loss of cholinergic 
basal forebrain (CBF) neurons (Bartus et al., 1982). This hypothesis is supported by 
many studies which demonstrate that the loss of CBF neurons occurs early in the disease 
progression, likely before a clinical diagnosis is reached (Bartus et al., 1982; Bowen et 
al., 1982; Beach et al., 1997; Beach et al., 2000). Also, the severity of the dementia in AD 
is highly correlated with the amount of cholinergic loss (Perry et al., 1981). Furthermore, 
the first drugs to be developed for AD have targeted the cholinergic system with 
moderate effectiveness. Donepezil, the first FDA-approved drug for AD and also the 
most widely prescribed, has shown to be effective at ameliorating behavioral symptoms 
associated with learning and memory in the early stages of the disease (Rogers et al., 
2000). Donepezil is an acetylcholinesterase (AChE) inhibitor, effectively reducing the 
extent of the breakdown of ACh and increasing the available amount of ACh at the 
synapse (Sugimoto et al., 1990). It has long been thought that AChE inhibitors only have 
the ability to alleviate the symptoms of AD, but recent studies suggest they may have 
disease-modifying effects as well (Sabbagh et al., 2006). One possible explanation as to 
why these CBF neurons are dying is related to calcium levels and excitotoxicity (Lucas & 
Newhouse, 1957). 
Excitotoxicity results from the overload or overabundance of calcium ions in 
neurons, and can be caused by the excessive activation of several receptors including 
glutamate receptors (Lucas & Newhouse, 1957). This excessive receptor activation can 
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lead to a large and persistent influx of calcium into the cell which produces too much 
excitation that can lead to cell death. Excitotoxicity has been tied to several 
neurodegenerative disorders including Huntington’s disease, amyotrophic lateral sclerosis 
(ALS), and AD (Mattson et al., 1992; Taylor-Robinson et al., 1994; Cluskey & Ramsden, 
2001). In AD specifically, increased calcium levels have been found in cells containing 
NFT and may even precede tangle formation (McKee et al., 1990). Furthermore, Aβ 
production is increased as a result of calcium influx in vitro (Querfurth & Selkoe, 1994). 
An endogenous neuropeptide that seems to be effective at reducing excitotoxicity and 
which has the capacity to protect neurons from overactivity (i.e. trophic properties) is 
galanin (Cortes et al., 1990).   
Galanin acts primarily as a neuromodulator in the central nervous system (CNS), 
interacting with several neurotransmitters including ACh, serotonin (5-HT), glutamate, 
and norepinephrine (Dutar et al., 1989; Pieribone et al., 1995; Kinney et al., 1998; Xu et 
al., 1998). Galanin is also overexpressed in AD, hyperinnervating surviving CBF neurons 
at concentrations as high as twice that of age-matched controls (Chan-Palay, 1988; Beal 
et al., 1990). When administered into the lateral ventricles or hippocampus of rodents, 
galanin has been shown to impair reference and working memory in several learning and 
memory tasks, including the Morris water task, T-maze delayed alternation, delayed non-
matching to position, starburst radial maze and trace fear conditioning (Mastropaolo et 
al., 1988; Robinson & Crawley, 1993; Ogren et al., 1996; Kinney et al., 2002; Kinney et 
al., 2003). Based on these findings, it is possible that galanin is contributing to the 
cognitive deficits observed in AD by inhibiting CBF neurons in an attempt to serve a 
neuroprotective role. One important question that has not been directly investigated is 
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whether galanin specifically modulating cholinergic tone may be responsible for the 
learning impairments above, which would have large implications for galanin in AD. 
 
Research Questions 
The present study investigated in experiment 1 if donepezil, the aforementioned 
AChE inhibitor, was able to rescue any of the cognitive impairment induced by central 
galanin administration consistent with other investigations. Because galanin has been 
shown to inhibit cholinergic signaling (Fisone et al., 1987), donepezil may be able to 
reverse the galanin-induced deficit by increasing cholinergic tone. If donepezil is able to 
rescue the learning and memory deficits in the galanin-infused animals, then it suggests 
that galanin may produce a deficit by modulating cholinergic mechanisms. However, if 
donepezil is unable to significantly rescue the galanin-induced deficit, it is likely the 
learning and memory impairments produced by galanin are unrelated to its suppression of 
cholinergic activity. Further, these data would also provide important information 
regarding the galanin-induced deficit reported in other studies. Such findings would 
indicate that galanin’s role in AD may not be as closely tied to the cholinergic system as 
the literature suggests. Either way, the first part of our study would provide crucial 
insight into galanin-ACh interactions, as well as perhaps answer some questions as to 
galanin’s role in AD.  
In experiment 2, we examined the effect that galanin and donepezil have on 
learning and memory, individually as well as in combination, following administration of 
the cholinergic neurotoxin, ethylcholine mustard aziridinium (AF64A). AF64A is a 
selective cytotoxin which specifically targets cholinergic neurons and produces 
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behavioral and histological deficits in the targeted region (for review see Smith, 1988). 
The effects of a cholinergic lesion on spatial learning and memory have been quite 
inconsistent with many studies finding a deficit while others have not (Walsh et al., 1984; 
Lamberty et al., 1992; Nakamura et al., 1992; Opello et al., 1993; Dornan et al., 1996; 
Bizon et al., 2003; Frick et al., 2004; Dashniani et al., 2009). The extent of the lesion and 
the amount of toxin administered likely influence whether or not deficits are observed 
following cholinergic-specific lesions. Our study utilized a relatively low dose of AF64A 
in order to damage but not fully destroy the cholinergic system. Further, our intent was to 
mimic the cholinergic loss observed in early or even pre-clinical AD necessitating a 
smaller dose of the toxin.  
We hypothesized that co-administration of donepezil and galanin following an 
AF64A-induced cholinergic lesion would in part rescue any learning and memory deficits 
caused by the toxin and potentially preserve a large number of cholinergic neurons. It 
may be possible that following the cholinergic lesion, galanin may preserve some 
cholinergic function, if it is in fact a trophic factor in vivo, and donepezil may 
behaviorally offset the AF64A-induced loss of ACh. If donepezil and galanin together are 
able to ameliorate the cognitive impairment and cell loss to a greater degree than just 
donepezil alone, then this finding would lend significant support to the argument for 
developing galanin agonists as an adjunctive treatment with donepezil in AD patients. 
Alternatively, if donepezil and galanin administration fails to improve performance or 
cholinergic neuron survival, this finding would suggest the utility of galanin antagonists 
in AD (if the increase in survival is absent, galanin may simply be exacerbating the 
cognitive impairment). Regardless of the findings, based on the overlap of the efficacy of 
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donepezil to ameliorate AD symptoms and the overexpression of galanin in AD, this 
investigation will contribute to the understanding of each of their roles in the disorder. 
We are genuinely surprised that there is no literature along these lines and this 
experiment should reveal insightful information about AD and the possible ways it can be 
therapeutically treated in the future. Below we have outlined a more comprehensive 
review of each of the aforementioned approaches and findings in AD. 
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CHAPTER 2 
REVIEW OF RELATED LITERATURE 
Amyloid β Hypothesis 
   The Aβ protein accumulates extracellularly in AD resulting in the formation of 
senile plaques, which may lead to cell damage and even cell loss. Aβ was first purified in 
1984 from cerebrovascular amyloid protein by Glenner & Wong and from senile plaques 
the next year by Masters et al. (1985), which was when its amino acid sequence was 
determined. Various mechanisms have been suggested to account for the neurotoxicity of 
Aβ peptides and senile plaques. Various studies have discovered a disruption in calcium 
homeostasis following Aβ administration which could potentially lead to excitotoxicity 
and cell loss. Further, it has been suggested that plaques may disturb surrounding 
cytoskeletal elements by “squishing” nearby cells. Although the mechanism by which Aβ 
contributes to neurodegeneration remains to be conclusively demonstrated, how the 
peptide is formed has been better characterized. 
 Aβ is formed by the proteolytic processing of its precursor protein, APP. APP is 
a membrane-spanning protein encoded for on chromosome 21. The APP gene product 
appears to be involved with synaptic transmission, axonal transport, cell adhesion and 
support, and cholesterol metabolism (for review, see Selkoe, 1994). Knockout 
(elimination of the gene product) and knockdown (reduction in the relative amount of a 
gene product) studies of APP have provided extensive information about its function. 
APP seems to play a role in muscle development or function, and has also been 
implicated in the formation of long-term potentiation (LTP), a cellular process argued to 
be essential for learning (Douglas & Goddard, 1975; Kauer et al., 1988; Dawson et al., 
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1999; Seabrook et al., 1999; Senechal et al., 2008). Under normal conditions, the APP 
protein is degraded via a series of events.  
The proteolytic processing of APP results in Aβ fragments of varying length, 
depending on where APP is cleaved by specific enzymes called secretases (Shoji et al., 
1992; Sisodia & Price, 1995). If APP is cleaved by alpha (α)-secretase, a soluble form of 
APP (sAPP) is secreted which is readily absorbed and processed by lysosomal proteolytic 
events. Cleavage by α-secretase occurs in the extracellular domain of APP within the Aβ 
sequence, thus preventing the formation of longer, neurotoxic forms of the Aβ peptide 
(Lannfelt et al., 1995). The senile plaques seen in AD are primarily made of the 40 and 
42 amino acid Aβ peptides, with studies showing that the 42 amino acid Aβ is more 
neurotoxic, i.e. more damaging to neurons, than the shorter variants (Roher et al., 1996). 
If APP is cleaved by beta (β) and gamma (γ)-secretases, this leads to formation of an Aβ 
peptide 39-43 amino acids long, which is similar to the lengths of Aβ predominantly 
found in senile plaques in AD (Golde et al., 1992; Citron et al., 1996).  
Initially, β-secretase (i.e. BACE) cleaves APP at its amino-terminus in the 
extracellular domain which is followed by cleavage by γ-secretase within the 
transmembrane domain (Vassar et al., 1999). BACE-1 inhibitors have been demonstrated 
to inhibit β-cleavage of APP and effectively lower Aβ levels in vitro and in vivo (Hussain 
et al., 2007). Inhibitors of γ-secretase have also been shown to reduce Aβ levels in the 
brain when administered to mice that overexpress a human mutant version of APP 
(Dovey et al., 2001). Inhibition of either of these two secretases theoretically leads to a 
reduction in the amount of Aβ because both β- and γ-secretase are necessary in order to 
cleave APP in a fashion that yields the 39-43 amino acid peptides known to aggregate 
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and form plaques. Considerable pharmacological research is being directed at developing 
β- and γ-secretase inhibitors as therapeutic targets in an effort to reduce plaque load and 
perhaps even halt the progression of the disease. A great deal of research has also been 
conducted examining the genetic underpinnings of AD with a particular focus on genes 
tied to the proteolytic processing of Aβ.  
Genetic linkage studies have tied familial forms of AD to the gene for APP on 
chromosome 21 (Goate et al., 1991; Citron et al., 1992). Over twenty mutations in the 
gene have been identified to date that are thought to be responsible for the familial early-
onset form of the disease (Chai, 2007). Individuals with any of these mutations have a 
slightly increased chance, compared to the population as a whole, of developing early-
onset AD because they have a greater amount of APP and thus produce more Aβ than 
normal individuals (Citron et al., 1992; Suzuki et al., 1994). Interestingly, almost all APP 
mutations are located within or adjacent to the Aβ peptide region of the precursor protein, 
and thus may affect the proteolytic processing of APP (Schellenberg, 1995). Related to 
the processing of APP are the presenilin (PS) genes which have also been implicated in 
autosomal dominant familial AD. 
Presenilins have been linked to early-onset AD, specifically PS-1 on chromosome 
14 and PS-2 on chromosome 1 (Levy-Lahad et al., 1995; Sherrington et al., 1995). 
Similar to the aforementioned mutations in APP, PS mutations lead to increased Aβ 
production, especially production of Aβ42, a species of the peptide known to be most 
toxic to neurons and overabundant in AD (Iwatsubo et al., 1994; Duff et al., 1996; Citron 
et al., 1997). Investigations into PS mutations and Aβ deposition have shown that 
mutations in the PS gene increase the ratio of Aβ42 versus Aβ40 as compared to non-PS 
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mutant cases of AD (Borchelt et al., 1996). This shift in the production of Aβ42 can have 
significant consequences, as many studies have suggested that Aβ42 aggregates more 
readily than Aβ40 and is deposited early in the formation of plaques (Jarrett et al., 1993; 
Iwatsubo et al., 1994). Furthermore, PS mutations seem to alter APP or Aβ processing by 
increasing the amount of cleavage by γ-secretase, and thus increasing the amount of 
insoluble Aβ released (DeStrooper et al., 1998; Wolfe et al., 1999). Knockout studies 
with animals that do not express the PS-1 and PS-2 genes show an abolishment of γ-
secretase mediated cleavage of APP (Steiner et al., 1999; Yu et al., 2001).  
Based on these findings and others, Wolfe et al. (1999) proposed the hypothesis 
that PS itself is a γ-secretase, an intramembranous protease that is responsible for γ-
cleavage of APP. Despite further evidence supporting this hypothesis, it appears that PS 
and γ-secretase are not the same protein even though they are highly related (Takasugi et 
al., 2003). Also, although PS-knockout mice seem to exhibit a complete abolishment of 
γ-secretase activity, these animals still produce Aβ42 peptide fragments, suggesting there 
are additional enzymes with activity similar to γ-secretase (Wilson et al., 2002). While 
the discovery that these three genes (APP, PS-1, and PS-2) are linked to familial AD 
advanced the investigation of the disorder, it is important to recognize that they 
collectively only account for about 10% of all familial early-onset cases (Cruts et al., 
1998). Given that more than 95% of AD cases occur after the age of 60, it is clear that 
these genetic mutations contribute only minimally to the risk of developing the more 
common variant of the disease (Holmes, 2002). With that said, much more is known 
about the genetics of familial early-onset AD than about sporadic, late-onset AD. 
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One gene implicated in non-familial forms of AD is the gene coding for 
Apolipoprotein E (ApoE). ApoE is a protein critical in regulating brain Aβ peptide levels 
and trafficking lipids throughout the brain (for review, see Holtzman, 2001). ApoE is 
responsible for clearing Aβ peptides from the brain across the blood-brain barrier into the 
peripheral circulation (LaDu et al., 1994; LaDu et al., 1995; Morikawa et al., 2005). Aβ 
peptides are normally generated at very high levels in the brain and are cleared at an 
equivalent rate (Bateman et al., 2006). Thus, even small reductions in the clearance of Aβ 
could result in elevated levels of Aβ peptides and eventual plaque formation. The 
lipidation status of ApoE appears to be important with regard to how well it can bind to 
Aβ and clear the peptide from the brain (Tokuda et al., 2000). If ApoE is in a lipidated 
form, it is more effective at clearing Aβ than if it is non-lipidated.  
Another way that Aβ is cleared from the brain is through a proteolytic mechanism 
involving either neprilysin (NEP) (Iwata et al., 2000) or insulin-degrading enzyme (IDE) 
(Kurochkin & Goto, 1994). Inhibition of either of these proteinases leads to a substantial 
elevation of Aβ levels in the brain and increased plaque deposition (Dolev and 
Michaelson, 2004). Recent research suggests that ApoE facilitates these enzymes, 
allowing them to degrade Aβ (Jiang et al., 2008). The ability of ApoE to clear Aβ is also 
dependent upon the isoform or allele of ApoE (Corder et al., 1993).  
ApoE has three alleles: ApoE-ε2, ApoE-ε3, and ApoE-ε4, with one or two copies 
of the ε4 allele leading to an increased risk of developing AD (Corder et al., 1993). 
Studies with transgenic mice overexpressing APP have demonstrated ApoE isoform-
specific effects on the ability of each allele to clear Aβ from the brain. The most effective 
allele at eliminating Aβ is the ε2 allele, followed by the ε3 allele, with the least effective 
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being the ε4 allele (Holtzman, 2004). Thus, individuals with one or two ε4 alleles (two 
alleles being the least effective possible form) of ApoE have a less effective mechanism 
for clearing Aβ from the brain, resulting in increased levels of the peptide (Saunders et 
al., 1993). In fact, a genetic study done by Corder et al. (1993) showed that over 90% of 
subjects examined who had two copies of the ε4 allele (4/4) had AD. Almost 50% of 
subjects with one copy of the ε3 and one copy of the ε4 (3/4) were affected with AD. 
Only about 20% of subjects with no copies of the ε4 allele (2/2, 3/3, or 2/3) had the 
disease. Corder et al. (1993) also looked at the average age of onset in individuals with 
one or two copies of the ε4 allele. The authors found that expression of it leads to a 
significantly earlier age of onset, with two copies of the ε4 allele leading to an earlier 
onset than just one copy. While the discovery of the ApoE gene and its relation to Aβ is 
critical to understanding AD pathogenesis, it is not a determinant of the disease and it 
must be regarded carefully. A consequence of the Aβ pathology that arises due to these 
mutations may be an initiation of the inflammatory response, a common neurological 
occurrence in individuals with AD. 
Glial cells in the brain, specifically microglia and astrocytes, can serve as 
mediators of the inflammatory response when necessary, defending the CNS from 
pathogens and aiding in the recovery from damage and stress (reviewed in Skaper, 2007). 
AD brains exhibit extensive localized activation of both microglia and astrocytes in 
response to neuronal and synaptic damage and Aβ accumulation (reviewed in Akiyama et 
al., 2000). It is likely this inflammation related to AD pathology may be both beneficial 
as a mechanism to promote neuronal survival and detrimental to AD brain function and 
the degeneration process (Wyss-Coray & Mucke, 2002). Recent studies have shown that 
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aggregated Aβ is itself capable of activating the inflammatory response by activating 
microglia and enhancing the synthesis and release of proinflammatory cytokines (Tan et 
al., 1999; Combs et al., 2001). These proinflammatory cytokines may also accelerate tau 
pathology and NFT formation, perhaps linking Aβ-induced inflammation and 
neurofibrillary pathology (Sheng et al., 2000; Quintanilla et al., 2004; Guo et al., 2006). 
This finding would suggest that inflammation is actually advancing AD pathology and 
accelerating the neuronal loss. Although microglial activation in AD may be caused by 
Aβ pathology, microglial activity correlates more closely with NFT pathology (Hayes et 
al., 2002). This relationship suggests that although Aβ may trigger the initial activation of 
microglia, the resulting inflammatory response may be more directly related to tau 
pathology (Blurton-Jones & LaFerla, 2006). Another study done by Guo et al. (2006) 
suggests that soluble Aβ and tau may directly interact to promote each other’s 
aggregation. In fact, it has been demonstrated that in vitro injection of Aβ activates GSK-
3β, one of the enzymes thought to be responsible for phosphorylating tau (Lovestone et 
al., 1996). Thus, it is clear there is some relation between Aβ and tau pathology, but more 
studies are needed to clarify the connection.  
Much of the above research eventually led to the amyloid cascade hypothesis 
which suggests that abnormal Aβ production and accumulation triggers the 
neurodegeneration seen in AD. Hardy & Higgins (1992) proposed that deposition of Aβ 
protein is the causative factor in AD pathology and that the NFT, neuronal loss, and 
dementia that follow are a result of this deposition. They hypothesized that neurotoxic Aβ 
peptides disrupt calcium homeostasis extracellularly and disrupt calcium concentrations 
intracellularly. This intra-neuronal increase in calcium concentration could potentially be 
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what causes tau proteins within the cell to be hyperphosphorylated and form PHF, which 
are the primary component of NFT. Thus, for this interpretation of the amyloid cascade 
hypothesis to be correct, elevations in Aβ levels should cause hyperphosphorylation of 
tau and neurofibrillary pathology to develop. This link between Aβ and tau has been 
verified to some extent in animal models and in cell culture, wherein Aβ causes an 
increase in tau phosphorylation (Gotz et al., 2001; Lewis et al., 2001; Zheng et al., 2002). 
Transgenic mice harboring mutations in both human APP and human Tau, as well as a 
mutant PS-1 allele, dubbed 3xTg-AD mice, develop both Aβ deposits and NFT-like 
pathology (Oddo et al., 2003a). Studies using these mice have demonstrated that Aβ 
accumulation precedes the development of tau pathology by several months, further 
suggesting Aβ may promote tau phosphorylation and aggregation (Oddo et al., 2003b).  
Despite the amount of research supporting the amyloid cascade hypothesis, there 
are several gaps between the hypothesis and data collected. First, the hypothesis is 
inconsistent with the presence of senile plaques in normal aged brains similar to those 
seen in AD (Crystal et al., 1988; Katzman et al., 1988; Price et al., 1991). If Aβ deposits 
are the catalyst for AD neurodegeneration, then we would not see individuals with no 
cognitive impairment and diffuse plaque load. Secondly, in transgenic animals that 
overexpress either APP or one of the PS mutations, there is no significant NFT formation 
or neurodegeneration despite considerable Aβ plaque load (Hsiao et al., 1996; Takeuchi 
et al., 2000). Because no AD-like pathology develops in these mice except for the 
plaques, it is difficult to argue that Aβ is directly causing the significant neuronal loss 
seen in the disease. Another limitation of the amyloid cascade hypothesis is that 
neurodegeneration and dementia occur in the absence of Aβ plaques in several diseases 
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related to the tau protein (Hutton et al., 1998; Spillantini et al., 1998). Regardless of 
whether or not Aβ peptides are the causative agent in AD, it is likely that they contribute 
to the cognitive symptoms seen in the disease, as well as have some effect on the 
pathogenesis in AD. Another pathogenic contributor to the neurodegeneration observed 
in AD is the tau protein which is hyperphosphorylated resulting in NFTs and neuronal 
loss.  
 
Tau Hypothesis 
Tau is an intracellular protein found abundantly in the central and peripheral 
nervous systems and is critical for microtubule stability and assembly, as well as 
microtubule flexibility (Goedert et al., 1989; Goedert et al., 1992). Microtubules are 
located throughout the neuron and in the axon and are essential for neurotransmission, 
axonal transport and axonal support (Paulson & McClure, 1974; Weingarten et al., 1975; 
Kraemer et al., 2003). Tau is a phosphoprotein which implies that it requires 
phosphorylation, or the addition of a phosphate group, in order for it to become activated 
(Butler & Shelanski, 1986). Tau is partially phosphorylated in the normal brain and this 
phosphorylation may regulate microtubule stability and assembly. This microtubule 
regulation appears to happen by reducing tau’s binding to tubulin, a protein that makes up 
microtubules, and reducing the promotion of microtubule assembly (Hasegawa, 2004). 
Thus, the phosphorylation of tau plays a pivotal role in regulating microtubule production 
by reducing the amount of microtubule assembly and decreasing the ability of tau to bind 
to tubulin.  
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In AD, the tau protein is hyperphosphorylated, which leads to the destruction of 
microtubule assemblies via the aforementioned mechanisms (Grundke-Iqbal et al., 1986). 
The degradation of microtubules may cause impaired axonal transport and possibly cell 
death (Kosik et al., 1986). Tau hyperphosphorylation renders tau unable to bind to 
microtubules, an event proposed to be responsible for self-assembly into the paired 
helical filaments (PHFs) (Goedert et al., 1988; Bramblett et al., 1993; Yoshida & Ihara, 
1993). These PHFs, which are primarily made up of hyperphosphorylated tau, correlate 
strongly with neuronal death in AD (Gomez-Isla et al., 1997). Also, whereas Aβ 
pathology is relatively specific to AD, NFT formation occurs in other diseases/disorders 
related to tau, collectively referred to as tauopathies. 
In 1998, several mutations in the tau gene were discovered in families with 
frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), a 
related but distinct neurodegenerative disease, indicating genetic evidence that tau 
abnormalities may be sufficient to lead to neurodegeneration (Hong et al., 1998; Hutton 
et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998). This discovery led to the 
production of many different transgenic lines of mice with tau mutations. One specific 
line, the P301L mice, shows significant age-dependent NFT formation, memory 
impairment, and neuron loss (Lewis et al., 2000; Ramsden et al., 2005). Although there is 
significant neurodegeneration in these animals, they do not develop any Aβ pathology, 
implying that tau mutation or tangle formation is not sufficient on its own to cause senile 
plaques in an animal model of AD. These findings provide strong evidence that tau may 
induce neuronal loss in the absence of Aβ, but also suggest that Aβ plaque formation may 
lie upstream of tau, at least for AD.  
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Consistent with the findings that Aβ plaque burden does not correlate well with 
the severity of dementia, but NFT formation does, is the finding that NFTs can be 
differentiated into neuropathological stages in AD. Braak & Braak (1991) reported 
detailed pathological studies about the distribution of plaques and tangles in autopsy 
brains of demented and non-demented individuals. They showed that Aβ deposition was 
of little significance in relation to neuropathological staging, whereas NFTs exhibited a 
neuroanatomical distribution pattern permitting the differentiation of six stages of disease 
progression in AD. Tangles are first observed in the entorhinal cortex where neuronal 
loss occurs the earliest, and are closely related to the initial memory impairment in AD, 
whereas Aβ deposits are not found in the hippocampal formation until the late stages of 
the disease (Hasegawa, 2004). Another post-mortem study showed that both NFTs and 
neuronal loss increased in parallel with the duration of AD, although the amount of 
neuronal loss was five or six times larger than the amount of tangle accumulation 
(Gomez-Isla et al., 1997). In contrast, the authors also found that the amount of plaques 
and Aβ accumulation were not related to neuronal loss, the number of NFTs, or the 
duration of the disease.  
Despite the recent attention the tau hypothesis has received, it has limitations 
similar to the Aβ hypothesis. Foremost is the finding that NFTs are extremely common 
and perhaps universal in the nucleus basalis of Meynert, a basal forebrain region rich in 
cholinergic fibers, in non-demented aged individuals (Beach et al., 1998). Secondly, 
because animal models of tauopathies fail to develop Aβ pathology or the global neuronal 
loss seen in AD, it is difficult to claim that tau aggregation and NFTs are causing the 
disease. Another possible explanation for the significant neuronal loss and degeneration 
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seen in AD is related to the cholinergic hypothesis and the loss of cholinergic neurons in 
areas important for learning and memory. 
 
Cholinergic Hypothesis 
The cholinergic deficit in AD is the earliest and most frequently reproduced 
finding, specifically the profound reduction in choline acetyltransferase (ChAT) activity 
(Davies & Maloney, 1976; Bowen et al., 1982). ChAT is the enzyme responsible for 
synthesizing acetylcholine (ACh), and its decreased activity leads to reduced amounts of 
available ACh in the brain, specifically in the hippocampus and neocortex (Perry et al., 
1977; Davies, 1979). The finding that cholinergic cell loss is associated with the presence 
of plaques in non-demented aged individuals suggests that the loss of cholinergic neurons 
precedes the clinical diagnosis of AD (Beach et al., 1997). Furthermore, studies indicate 
that the severity of the dementia in AD correlates well with the extent of cholinergic loss 
and the reduction in ChAT activity in the cortex (Perry et al., 1981). Cholinergic loss 
occurs first and foremost in the basal forebrain where CBF neurons deteriorate very early 
in the disease progression (Whitehouse et al., 1982; Bowen et al., 1982; Beach et al., 
2000). ACh has been implicated in different cognitive functions such as learning and 
memory (Whitehouse, 1967; Cox & Tye, 1973; Valentino & Dingledine, 1981; Spencer 
& Lal, 1983; Spencer et al., 1985; Woolf, 1996). Once ACh is released, it can bind to 
either of two receptor subtypes: nicotinic acetylcholine receptors or muscarinic 
acetylcholine receptors (Role & Berg, 1996; reviewed in Wevers & Schroder, 1999 and 
Ishii & Kurachi, 2003).  
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Nicotinic receptors are ionotropic receptors (receptors that can open ion channels 
when ACh binds to them) while muscarinic receptors are metabotropic receptors 
(receptors that activate a G-protein and trigger intracellular events when ACh binds, 
including the opening of multiple ion channels). There appears to be a selective loss of 
ACh receptors in the cortex and hippocampus in AD, and it seems to be more pronounced 
for nicotinic receptors (Flynn & Mash, 1986; Perry et al., 1995; Wevers et al., 2000).  
Nicotinic receptor activation using nicotine produces a significant increase in the 
amount of phosphorylated tau both in vitro and in 3xTg-AD mice (Hellstrom-Lindahl et 
al., 2000; Oddo et al., 2005). The exact mechanism of how this increase in 
phosphorylation occurs remains unclear, but it may be a result of increased calcium levels 
due to overactivation of the nicotinic receptors. Nicotonic receptors are one of only a few 
ionotropic receptors in the brain that allow an influx of calcium ions when ACh binds 
(McGehee et al., 1995; Role & Berg, 1996). This increase in intracellular calcium may 
activate different calcium-dependent kinases, such as GSK3β or p38MAP kinase, which 
may be responsible for phosphorylating tau (Oddo et al., 2005). Nicotinic receptor 
activation also appears to have an effect on Aβ deposits in the brain. In vitro studies have 
shown that nicotine seems to inhibit Aβ fibril formation and also disrupts already formed 
fibrils (Salomon et al., 1996; Zeng et al., 2001; Ono et al., 2002). This would suggest that 
in the absence of ACh, the formation of fibrils is allowed to progress at a more rapid rate. 
Studies using transgenic mice, specifically mice that overexpress human APP called 
Tg2576, showed a dramatic decrease both in Aβ plaque burden and the levels of 
insoluble Aβ40 and Aβ42 after chronic administration of nicotine for a period of five and 
a half months (Nordberg et al., 2002). It is difficult to determine what effect the loss of 
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nicotinic receptors has on tau phosphorylation and Aβ deposits in AD, and more studies 
are necessary to elucidate the relationships. 
Muscarinic receptors, specifically the M1 receptor subtype, are highly expressed 
in the cerebral cortex and hippocampus, and seem to be particularly relevant to memory 
function in AD (Anagnostaras et al., 2003). The M1 receptor has been shown to decrease 
tau phosphorylation suggesting that decreased cholinergic activity may lead to 
destabilization of the microtubule network and eventual tangle formation. In vitro studies 
using cholinergic M1 agonists showed that the muscarinic-activated decrease of tau 
phosphorylation was both time and dose dependent (Sadot et al., 1996). In vivo studies 
using 3xTg-AD mice also showed a reduction in tau phosphorylation after administration 
of a muscarinic agonist and conversely showed increased tau phosphorylation after 
treatment with an M1 antagonist (Caccamo et al., 2006). Previous in vitro findings found 
that M1 receptor agonists decrease tau phosphorylation by the reduction of GSK3β 
activity (Forlenza et al., 2000), which appears to be the mechanism by which tau 
phosphorylation was decreased in the 3xTg-AD mice. Muscarinic receptor activation also 
appears to reduce Aβ production and increase the secretion of soluble APP (Buxbaum et 
al., 1992). In the 3xTg-AD mice, an M1 agonist reduced Aβ deposition in the 
hippocampus and cortex, and ameliorated cognitive deficits in a spatial memory task 
(Caccamo et al., 2006). This finding that muscarinic activation regulates APP processing 
(Nitsch et al., 1992) formed the basis for the hypothesis that AChE inhibitors may slow 
disease progression by reducing Aβ production (Inestrosa et al., 1996).  
AChE inhibitors were developed as a result of the cholinergic hypothesis in order 
to increase cholinergic tone in individuals with AD (Davis et al., 1978; Bartus, 1979; 
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Bartus et al., 1982). AChE is primarily responsible for the breakdown of ACh into 
choline and acetic acid. AChE has also been implicated in Aβ plaque formation and 
appears to have the ability to accelerate Aβ formation and deposition in AD (Inestrosa et 
al., 1996). Therefore, by inhibiting the enzymatic activity of AChE, it may be possible to 
reduce Aβ plaque formation and ameliorate AD symptomology. AChE inhibitors increase 
the amount of ACh available in the synapse as well as enhance and prolong its action on 
ACh receptors (Harvey & Rowan, 1990). AChE inhibitors have been approved for use in 
mild to moderate AD and have been shown to improve cognitive deficits (Rogers et al., 
1998; Rosler et al., 1999; Tariot et al., 2000). One of the most widely prescribed and used 
AChE inhibitors is donepezil.  
Donepezil hydrochloride is a piperidine-based, non-competitive, reversible 
inhibitor of AChE with high central nervous system specificity and a long duration of 
action (Yamanishi et al., 1991). It has been demonstrated to be a well-tolerated drug that 
improves cognitive performance and global function in mild to moderate AD patients 
(Rogers et al., 1996; Rogers et al., 1998). Donepezil significantly increases extracellular 
ACh concentrations both dose- and time-dependently (Kosasa et al., 1999). Furthermore, 
donepezil was able to significantly improve a deficit in spatial learning and memory 
induced in rats with lesions of the medial septum, a pathway by which cholinergic 
neurons project to the hippocampus, at a relatively low dose of 0.5 mg/kg. The rescue of 
the spatial deficit was almost to the level of the control animals in a Morris water maze 
(MWM) spatial learning task (Ogura et al., 2000). Scopolamine, a cholinergic antagonist, 
has been shown to produce learning impairments in rodents (Ogren et al., 1998; Elvander 
et al., 2004). Donepezil, once again at a low dose of 0.5 mg/kg, was able to significantly 
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decrease the scopolamine-induced deficit in rats in an 8-arm radial arm maze, a spatial 
learning and memory task (Ogura et al., 2000).  
Many animal models of AD show Aβ pathology and a few even show tau 
pathology, but thus far none have been able to replicate the global neuronal loss exhibited 
in AD. Nevertheless, administration of donepezil to different AD models provides 
valuable insight into the cellular and molecular effects of the drug, as well as examines 
the effect it has on behavioral deficits. One such animal model involves lesions of the 
entorhinal cortex, a part of the brain which provides inputs to the hippocampus, using 
ibotenic acid, a compound that produces non-specific excitotoxic lesions. Although the 
lesion does not model the specific cholinergic loss which is a hallmark of AD, it is a 
valuable tool to study hippocampal learning and memory deficits. One study 
administered donepezil following an ibotenic acid lesion and found that donepezil was 
able to partially rescue the lesion-induced deficit in the MWM (Spowart-Manning & van 
der Staay, 2005).  
Further animal models are the Tg2576 mice and APP23 mice that overexpress 
human APP containing the Swedish double mutation and display age-related cognitive 
deficits and plaque load (Hsiao et al., 1996; Sturchler-Pierrat et al., 1997; Kelly et al., 
2003). Briefly, the gene coding for APP is mutated to overexpress the protein and the 
mice eventually develop Aβ plaques around 6 months of age (Sturchler-Pierrat et al., 
1997). A study with the Tg2576 mice showed that donepezil administration dose-
dependently (0.1, 0.3, or 1.0 mg/kg) reduced the cognitive deficit in a spatial memory 
task (Dong et al., 2005). Another study investigated the effect of donepezil administration 
(0.3 mg/kg) in the APP23 transgenic mice and found that it was able to rescue some of 
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the deficits in the MWM (Van Dam et al., 2005). In a follow-up study using the APP23 
mice, Van Dam et al. (2008) found that donepezil may have disease-modifying effects. 
After chronic donepezil treatment (0.27 mg/kg per day for 8 weeks), animals experienced 
a 3 week wash-out period where no drug was given in order to determine if treatment was 
able to improve spatial memory in the MWM after the drug was no longer active. 
Donepezil significantly improved performance of the APP23 mice both in acquisition and 
retention of spatial memory in the MWM. This possible disease-modifying effect of 
donepezil may be due to the relation between AChE and Aβ formation that we previously 
reviewed. Because AChE has been implicated in amyloid plaque formation (Inestrosa et 
al., 1996), the inhibition of AChE may lead to reduced Aβ pathology. In fact, donepezil 
in vitro reduced AChE-induced Aβ aggregation by 22% (Bartolini et al., 2003). Further 
evidence from in vitro studies found donepezil, but not other AChE inhibitors, had 
neuroprotective effects on cell culture models of neuronal injury (Akasofu et al., 2008). 
 Another possible explanation for donepezil’s possible disease-modifying ability 
is that in addition to its action on AChE, it antagonizes N-methyl-D-aspartate (NMDA) 
receptors in the brain (Wang et al., 1999; Moriguchi et al., 2005). NMDA receptors are 
activated by glutamate, an excitatory neurotransmitter, and when NMDA is open it 
allows calcium ions into the cell. An overabundance of calcium ions can lead to 
excitotoxicity and neuronal death which is what may be occurring in AD (Lucas & 
Newhouse, 1957; Mattson et al., 1992). Thus, because donepezil is able to reduce the 
activity of the NMDA receptor, it also may reduce excitotoxicity. This excitotoxic 
inhibition may be mediated through nicotinic ACh receptors followed by specific kinases 
which reduce NMDA receptor activity (Takada-Takatori et al., 2006). Interestingly, 
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donepezil has also been found to improve cognitive performance in healthy young rats 
(Cutuli et al., 2008), which suggests donepezil may act as a cognitive enhancing drug in 
normal animals as well as in animals with cognitive deficits. 
 Donepezil is clearly able to ameliorate deficits related to AD pathology in early 
and middle stages of the disease in AD patients and in animal models (Rogers et al., 
2000). It increases cholinergic tone and activity, likely compensating for the profound 
deterioration of CBF neurons in AD. These findings also indicate why in the latter stages 
of AD donepezil has been found to be less effective, as the overall loss of cholinergic 
neurons may progress to a level beyond the capacity of an AChE inhibitor to improve. 
Although it is not yet evident why these CBF neurons begin dying in AD, one possible 
explanation is related to calcium levels and excitotoxicity. 
 
Excitotoxicity Approach 
 Glutamate is an excitatory neurotransmitter pervasively expressed throughout the 
central nervous system (Harvey & McIlwain, 1968). It can act on either ionotropic 
receptors such as AMPA, kainate or NMDA receptors, or metabotropic receptors which 
are coupled to G-proteins (Ishida & Neyton, 1985; O’Brien & Fischbach, 1986; Cull-
Candy & Usowicz, 1987; Jahr & Stevens, 1987). Binding of glutamate to NMDA 
receptors leads to an influx of calcium and excitation (MacDermott et al., 1986). Because 
glutamate is a potent excitatory transmitter, excessive amounts or prolonged release can 
elicit excessive excitation in neurons that may lead to cell death (Lucas & Newhouse, 
1957; Olney & Ho, 1970). Chronic exposure to moderately elevated glutamate levels or 
hyperactivity of glutamate receptors, which is what may be occurring in many 
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neurodegenerative diseases as well as cerebral ischemia, can lead to a steady influx of 
calcium which has been shown to be toxic for the cell (reviewed in Mattson & Chan, 
2003). This calcium-induced cell death, also called excitotoxicity, has been investigated 
in AD and may play a role in the progressive degeneration of neurons. 
 Calcium levels in AD appear to be elevated, potentially resulting in excitotoxicity 
and cell death (Peterson et al., 1985; Peterson & Goldman, 1986). Calcium levels are 
increased in neurons that contain NFTs as compared with tangle-free neurons (Murray et 
al., 1992). The increased levels of calcium may precede tangle formation based on the 
finding that levels of calcium/calmodulin-dependent protein kinase II (CamKII), the most 
abundant kinase in the brain and dependent on calcium for activation, are increased in 
hippocampal neurons which are vulnerable to degeneration (McKee et al., 1990). 
Calcium levels may also be affected by Aβ peptides. In vitro studies show that 
application of Aβ peptide increases the vulnerability of cortical neurons to glutamate 
toxicity (Mattson et al., 1992). In vivo, the toxicity caused by Aβ injection into the 
hippocampus or nucleus basalis of Meynert is reduced by NMDA antagonists, showing 
that the toxicity is in part related to glutamatergic activity (Harkany et al., 1999; Miguel-
Hidalgo et al., 2002). These studies suggest that glutamate receptor activation and 
exposure to Aβ peptides together are more injurious than either insult alone (Canzoniero 
& Snider, 2005). In addition to increasing vulnerability to calcium influx through 
glutamate receptors, specifically NMDA, Aβ can also increase resting calcium levels 
both intra- and extracellularly (Mattson et al., 1992). In an attempt to address the 
excitotoxic damage caused by increased calcium levels and overactivity of glutamate 
receptors, NMDA-receptor antagonists have been developed. 
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 Memantine is an uncompetitive NMDA antagonist that has been approved for use 
in moderate to severe cases of AD dementia (Ditzler, 1991; Winblad & Poritis, 1999; 
Tariot et al., 2004). What makes memantine an uncompetitive antagonist is that it 
becomes more effective at blocking NMDA receptors the more the receptors become 
activated. In other words, under normal physiological conditions, the NMDA receptor 
will not be antagonized by memantine because the drug will remain inactive. When the 
NMDA receptor is overactivated by glutamate, memantine becomes extremely effective 
at returning NMDA activity to a normal state. At a fixed concentration of memantine, its 
ability to block the NMDA receptor increased as the concentration of NMDA increased 
(Chen et al., 1992). For this reason memantine is usually only administered in later stages 
of AD when calcium concentrations may be sufficiently elevated and the drug is able to 
exert its unique uncompetitive NMDA blockade. Another way of possibly reducing the 
excitotoxicity seen in AD is via the endogenous peptide galanin, which has been shown 
to exhibit neuroprotective effects.  
 
Galanin Literature 
 Galanin is a 29 amino acid (30 in humans) neuropeptide, first isolated from 
porcine intestine by Tatemoto et al. (1983). It is widely expressed throughout the 
mammalian nervous system with galaninergic neurons in areas such as the cerebral 
cortex, nucleus basalis of Meynert, hippocampus, amygdala, and locus coeruleus 
(Kordower et al., 1992; Perez et al., 2001). Galanin inhibits several classical 
neurotransmitters including glutamate, serotonin, norepinephrine, and ACh (Dutar et al., 
1989; Pieribone et al., 1995; Robinson et al., 1996; Kinney et al., 1998; Ogren et al., 
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1998; Xu et al., 1998). In the basal forebrain of rodents, galanin co-localizes with 
cholinergic neurons within the medial septum/diagonal band complex (Melander et al., 
1985; Melander et al., 1986; Miller et al., 1998). In the human basal forebrain, there 
exists a small population of non-cholinergic galaninergic interneurons and a dense 
galaninergic fiber plexus that innervates CBF neurons (Mufson et al., 1993; Bowser et 
al., 1997). In fact, it was found that galanin immunoreactivity is present in ~50-70% of 
CBF neurons (Melander et al., 1985). These findings led to the hypothesis that galanin 
may mediate the cholinergic system related to cognitive function (Mufson et al., 1998). In 
vitro studies have demonstrated that galanin reduces ACh release and ACh-elicited 
excitation and also inhibits LTP in hippocampal neurons (Fisone et al., 1987; Dutar et al., 
1989; Palazzi et al., 1991; Sakurai et al., 1996). A different in vitro study found that 
galanin actually has the ability to excite cholinergic neurons, but further studies are 
needed to clarify this excitatory role for galanin (Jhamandas et al., 2002). In vivo work 
has shown that galanin administered into the hippocampus, lateral ventricles, or basal 
forebrain impairs cognitive performance on spatial learning and memory tasks in rats 
(McDonald et al., 1998; Wrenn & Crawley, 2001; Kinney et al., 2003). Furthermore, 
mice that overexpress galanin (GalOE) display cognitive deficits characteristic of AD 
(Steiner et al., 2001). Taken together, these data suggest that galanin may inhibit the basal 
forebrain and hippocampus to regulate cognitive processes.  
  Alternatively, galanin also appears to play a neurotrophic or neuroprotective role 
in the brain (Holmes et al., 2000; O’Meara et al., 2000; Mahoney et al., 2003; Elliot-Hunt 
et al., 2004; Elliot-Hunt et al., 2007). Following trauma or injury to the central nervous 
system, galanin expression is up-regulated in many brain regions (Cortes et al., 1990). 
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Galanin also acts as a survival and growth-promoting factor to neurons in both the central 
and peripheral nervous systems (Holmes et al., 2000; O’Meara et al., 2000; Mahoney et 
al., 2003). Zini et al. (1993) found that galanin reduces glutamate release by 50-60% in 
rat hippocampal slices. Because glutamate is the principle excitatory neurotransmitter in 
the brain, and it can be responsible for calcium-induced excitotoxicity, the ability of 
galanin to reduce glutamate release classifies it as a trophic factor. Elliot-Hunt et al. 
(2004) also found that galanin promotes hippocampal neuron survival in a number of in 
vitro models of excitotoxic injury. Using hippocampal slices from transgenic animals 
either over-expressing galanin (GalOE) or galanin knockout (GalKO), galanin was shown 
to exert a protective effect after administration of glutamate or staurosporine, an agent 
which inhibits protein kinase activity and can lead to apoptosis, or programmed cell 
death. Galanin has also been shown to protect neurons from the toxic effects of Aβ in 
vitro, further exhibiting its neuroprotective capacity (Ding et al., 2006). Due to this 
ability to reduce excitotoxic damage and protect from neuronal injury, galanin agonists 
have significant implications as anti-epileptic agents. In order to further understand 
galanin and its possible therapeutic effects, we must first examine its receptors which 
would ultimately be the targets of any drugs. 
 Galanin receptors are G-protein-coupled metabotropic receptors, which activate 
second messenger pathways after the binding of a ligand (Hulting et al., 1993; Walli et 
al., 1994; Branchek et al., 1998). The first galanin receptor (GAL-R1) is a Gi/o coupled 
receptor, which belongs to a family of receptors with mostly inhibitory actions. GAL-
R1’s are found throughout the human brain, particularly in the cortex, hippocampus, 
thalamus, and amygdala (Habert-Ortoli et al., 1994). Activation of GAL-R1 leads to 
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inhibition of adenylyl cyclase and cyclic adenosine monophosphate (cAMP), both of 
which are signal transduction mechanisms crucial for learning and memory processes, 
especially consolidation of memory (Palazzi et al., 1991; Karelson & Langel, 1998; 
Wang et al., 1998; Iismaa & Shine, 1999; Kinney et al., 2003).  
The second galanin receptor subtype (GAL-R2) can be of a Gq subtype or a Gi/o 
subtype, and can be either excitatory or inhibitory (Fathi et al., 1998; Wittau et al., 2000). 
GAL-R2’s are found in areas of the human brain similar to GAL-R1’s including the 
cortex, hippocampus, amygdala, thalamus, and cerebellum (Borowsky et al., 1998; Fathi 
et al., 1998). A key difference between the two receptor subtypes which may explain 
their different mechanisms of action is that they are found in different parts of the 
hippocampus and exert different effects when activated. The ventral hippocampus 
contains significantly more GAL-R1’s than the dorsal hippocampus which contains more 
GAL-R2’s (Melander et al., 1985; Melander et al., 1986; Fisone et al., 1987; O’Donnell 
et al., 1999). Accordingly, when galanin is injected directly into the ventral hippocampus 
where there is higher GAL-R1 expression, learning and memory was impaired in the 
Morris water task. Conversely, when galanin is injected into the dorsal hippocampus, no 
learning deficits were detected (Ogren et al., 1999). GAL-R2 activation appears to 
increase the levels of inositol phosphates and intracellular calcium in cell cultures, 
leading to increased LTP and synaptic plasticity (Fathi et al., 1998; Kolakowski et al., 
1998; Wang et al., 1998; Wittau et al., 2000). Thus, GAL-R2’s appear to activate 
phospholipase C and protein kinase C, initiating a signal transduction pathway which 
promotes neurotransmission and facilitates learning and memory. Furthermore, activation 
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of the GAL-R2 protects the hippocampus from neuronal damage, implicating this 
receptor subtype in the trophic role galanin plays (Elliot-Hunt et al., 2007).  
The third galanin receptor subtype (GAL-R3) appears to be similar to GAL-R1 in 
functionality, coupling to the Gi protein, however the prevalence of GAL-R3 within the 
CNS is much less extensive and considerably more studies are needed on this receptor 
(Kolakowski et al., 1998; Smith et al., 1998). Thus, depending on which galanin receptor 
is activated, the effect may be inhibitory or excitatory; a distinction necessary to make in 
order to understand what is occurring in AD. In AD, the overexpression of galanin may 
be inhibitory, further exacerbating cognitive deficits, or it may be neuroprotective, 
attempting to save CBF neurons from any further damage. 
 AD patients exhibit characteristic memory loss and learning deficits, especially in 
later stages of the disease. When galanin is centrally administered to rodents, it causes 
learning and memory deficits, specifically deficits in the consolidation of memory 
(Kinney et al., 2003). Because of this finding and others like it, it can be said that it is 
possible that the overexpression of galanin seen in AD is contributing to the cognitive 
impairments exhibited in the disease. The mechanism by which galanin may contribute to 
the cognitive impairment has not been clarified, although many findings suggest it is 
through interactions with the cholinergic system (Fisone et al., 1987; Chan-Palay, 1988; 
Dutar et al., 1989; Mufson et al., 1993).  
 The loss of CBF neurons in AD is accompanied by an increase in the activity of 
the surviving cholinergic neurons (McDonald & Crawley, 1997). Because of galanin’s 
role as an inhibitory neuromodulator, this increase in cholinergic activity may increase 
galaninergic activity, thus inhibiting the remaining cholinergic neurons (Fisone et al., 
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1987; Chan-Palay, 1988; Chan-Palay, 1990; Mufson et al., 1993; Bowser et al., 1997). 
The inhibition of surviving cholinergic neurons may then lead to the learning and 
memory problems characteristic of late-stage AD, because of the aforementioned 
importance of acetylcholine in learning and attentional processes. This theory is 
supported by findings that galanin expression progressively increases in the basal 
forebrain in AD (Mufson et al., 2000). Galaninergic fibers form a dense plexus 
surrounding surviving CBF neurons, reaching concentrations twice that of age-matched 
controls (Beal et al., 1990). Although there is evidence of increased galaninergic activity 
early in the disease progression (Perez et al., 2002), it appears that galanin 
hyperinnervation of CBF neurons only occurs in the late stage of the disease (Chan-
Palay, 1988; Mufson et al., 1993; Bowser et al., 1997; Mufson et al., 2000; Counts et al., 
2006). These findings are consistent with the notion that galanin overexpression is 
triggered by neuronal damage, suggesting galanin hyperinnervation of CBF neurons 
represents a neuronal survival mechanism (Gabriel et al., 1995; Hartonian et al., 2002; 
Shen et al., 2003).  
In a recent study examining tissue from AD brains, it was found that CBF neurons 
that are hyperinnervated by galanin show a significant increase in choline 
acetyltransferase (ChAT) expression as compared to CBF neurons that have no GAL 
hyperinnervation (Counts et al., 2008). The increase in ChAT due to galaninergic 
hyperinnervation observed in this study suggests a neuroprotective role for galanin in 
AD. In a study using saporin to produce a cholinergic-specific lesion in the basal 
forebrain of rats, it was found that galanin immunoreactivity within and adjacent to the 
lesion was significantly increased as compared to control animals, an effect that persisted 
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long after the treatment (Hartonian et al., 2002). Thus, damage to cholinergic neurons 
would appear to be sufficient to increase galanin expression long-term as a trophic 
response to the damage. However, in Down’s syndrome which also produces extensive 
CBF degeneration, galanin does not hyperinnervate surviving cholinergic neurons 
(Mufson et al., 1993; Sendera et al., 2000). These findings suggest that CBF neuron loss 
alone is insufficient to trigger the galanin plasticity response seen in AD. Therefore, it 
may be that galanin is overexpressed in AD due to other factors such as the Aβ plaques or 
the NFT or the excitotoxicity. Whether galanin is protecting or inhibiting CBF neurons in 
AD is still unknown, but it is clear the neuropeptide needs to be studied further in order to 
fully understand its role in this neurodegenerative disease. 
 
Hypothesis and Implications 
 Many theories have been proposed to explain the neurodegeneration which occurs 
in AD, but none so far have been able to account for the massive neuronal loss and 
progressive cognitive decline seen in the disease. Galanin may provide a critical link in 
the causal chain of AD, and thus the current study has potential implications for future 
Alzheimer’s research. The effects of the co-administration of donepezil and galanin 
should provide valuable insight into AD pathology and further supplement the literature 
related to ACh and galanin.  
In a series of experiments we attempted to determine if galanin exerts its effects 
on learning and memory via modulation of cholinergic tone in an intact nervous system, 
as well as to examine its effects in an animal model of AD when co-administered with a 
drug that is used to treat the disorder. In experiment 1, we investigated the effects of 
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galanin when co-administered with donepezil in a spatial learning task, the Morris water 
maze, in an effort to clarify the mechanism by which galanin impairs learning and 
memory. If the galanin-induced deficit is altered by the addition of donepezil, it is likely 
galanin is impairing learning and memory in part via inhibition of cholinergic 
mechanisms. However, if donepezil has no effect on the galanin-induced deficit, then the 
deficit is likely unrelated to cholinergic alterations. Recent data from our lab indicate a 
drastic reduction in CREB (cAMP-response element binding protein) phosphorylation, a 
critical event for the induction of LTP and learning and memory (Comb et al., 1986; 
Dash et al., 1990; Bartsch et al., 1998), following galanin administration (Kinney et al., 
2009). In addition, these changes have been linked to the learning impairments observed 
following exogenous galanin administration (Kinney et al., 2003). Therefore, we 
hypothesized that donepezil would be unable to rescue the galanin-induced deficit, and 
that galanin’s inhibition of CREB phosphorylation may be principally responsible for the 
learning deficit. 
There is a paucity of evidence on the role galanin may play following a 
cholinergic lesion with regard to both the survivability of cholinergic neurons and 
learning and memory. In experiment 2, we examined the effects of donepezil and galanin 
following the central administration of a cholinergic-specific neurotoxin, AF64A, 
designed to mimic an early or even preclinical stage of AD. While previous 
investigations have been carried out on either the effectiveness of AChEIs following a 
cholinergic lesion or the potential role of galanin in AD, there have been no studies 
examining both galanin and AChEIs in a model consistent with AD. Whether or not 
galanin functions in a neuroprotective capacity following a cholinergic lesion as well as 
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how it affects learning following damage are key concepts that have yet to be addressed. 
In addition, we sought to determine what effect the co-administration of donepezil and 
galanin would have in a compromised cholinergic system. We hypothesized that 
donepezil would rescue any lesion-induced learning and memory deficits by increasing 
the amount of available ACh and restoring the functioning of the cholinergic system to a 
physiologically normative level. We further hypothesized that although galanin may not 
rescue the lesion-induced impairment, it may potentially reduce the degree of cell loss in 
these animals if it does act as a trophic factor in vivo. Finally, we expected that co-
administration of donepezil and galanin would lead to a partial rescue of the learning and 
memory deficits caused by AF64A. However, we hypothesized that the inhibitory effects 
of galanin would not allow a complete reversal of the lesion-induced deficits.  
 
 
 
 
 
 
 37 
 
CHAPTER 3 
MATERIALS AND METHODS 
Subjects 
 Ninety adult male Sprague-Dawley rats (forty for Experiment 1 and fifty for 
Experiment 2) approximately three months of age and weighing between 250 and 350 g 
were used. Rats were maintained in a temperature and humidity (22 ± 1°C) controlled 
facility, with food and water available ad libitum, on a 12:12 light/dark cycle, lights on at 
7:00 a.m. Animals were housed in pairs until the time of the surgery, after which they 
were individually housed. All procedures were approved by the University of Nevada, 
Las Vegas Institutional Animal Care and Use Committee and carried out in accordance 
with NIH guidelines for the appropriate care and use of animals.  
 
Surgery 
Surgeries were performed as described previously by Kinney et al. (2003). 
Briefly, all animals underwent stereotaxic surgery under aseptic conditions and ketamine 
(66 mg/kg; Henry Schein Inc, Sparks, NV) and dexmedetomidine (0.2 mg/kg; Henry 
Schein Inc, Sparks, NV) anesthesia. A guide cannula 1.4 cm in length, 24-gauge stainless 
steel hypodermic tubing (Plastics One, Roanoke, VA) was implanted into the right lateral 
ventricle at coordinates 0.5 mm posterior, 1.2 mm lateral to bregma, and 3.5 mm ventral 
to the surface of the skull (Paxinos & Watson, 1986). The cannula was secured to the 
skull using stainless steel screws and dental acrylic. A 31-gauge stylet was inserted to 
close the guide cannula. Rats were administered an analgesic (Buprenorphine, 0.05 
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mg/kg; Henry Schein Inc, Sparks, NV) immediately following surgery as well for two 
days post-surgery to minimize post-operative pain.  
 
Drug Treatments 
 Rat galanin 1-29 (Bachem Americas, Inc. Torrance, CA) was dissolved in 0.9% 
physiological saline vehicle at a concentration of 3 nmol/3 µl. Donepezil hydrochloride 
(Tecoland Corporation, Edison, NJ) was dissolved in 0.9% physiological saline to a 
concentration of 0.3 mg/kg. AF64A was dissolved in NaOh to a concentration of 0.34 
mg/ml and pH was adjusted to between 7.0 and 7.4. The toxin was administered into the 
right lateral ventricle, 2 µl total, over the course of one minute with the injector being left 
in for an additional minute to ensure complete distribution of the solution. Subjects were 
randomly assigned to different treatment groups, each of which consisted of a daily pre-
treatment administered intra-peritoneally (i.p. 1 ml/kg) and a daily treatment administered 
intracerebroventricularly (i.c.v. 3 µl infused). The pre-treatment was given 20 minutes 
prior to behavioral testing and the treatment was given 5 minutes before testing. Saline 
was administered as a control for i.p. pre-treatments and artificial cerebrospinal fluid 
(ACSF) was administered as a control for i.c.v. treatments.  
For the first experiment, a control group received a saline pre-treatment and a 
treatment of ACSF. The remaining three groups received daily administrations of either a 
donepezil pre-treatment and a treatment of ACSF, a saline pre-treatment and a treatment 
of galanin, or a pre-treatment of donepezil and a treatment of galanin. In Experiment 2, 
four of the five groups received a one-time infusion of AF64A an average of four days 
before behavioral testing began. A control group received a sham-lesion, using ACSF 
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instead of the toxin, and a pre-treatment of saline followed by treatment with ACSF. The 
remaining toxin-infused groups received daily administrations of either a pre-treatment of 
saline and a treatment of ACSF, pre-treatment of donepezil and a treatment of ACSF, 
pre-treatment of saline and a treatment of galanin, or pre-treatment of donepezil and a 
treatment of galanin. Table 1 outlines the drug administrations for each group in 
experiments 1 and 2.  
 
Table 1 
Experiment 1 
Pre-treatment Treatment 
Saline ACSF 
Donepezil ACSF 
Saline Galanin 
Donepezil Galanin 
 
Experiment 2 
Before Testing Pre-treatment Treatment 
Sham lesion Saline ACSF 
Lesion Saline ACSF 
Lesion Donepezil ACSF 
Lesion Saline Galanin 
Lesion Donepezil Galanin 
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Morris Water Task 
 The Morris water task was conducted in a circular tank, 1.8 m in diameter 
and 76 cm in height, made of white polyethylene 4.7 mm in thickness (San Diego 
Instruments, San Diego, CA). Tap water, 48 cm deep, was maintained at a temperature of 
25°C and made opaque by the addition of white non-toxic paint (Fresco Tempera Paint, 
Rich Art Color Company, Northvale, NJ), and changed every other day. The escape 
platform, a square platform 10 cm in diameter made of clear plastic, was placed in the 
center of one of the four quadrants (target quadrant), 30 cm from the inside wall of the 
maze and 1.5 cm below the surface of the water. For visible platform training, a large 
black and white cover was attached to the top of the platform and protruded 2 cm above 
the water.  
 Trials were recorded and captured using a video tracking system (Smart, San 
Diego Instruments, San Diego, CA) recorded from a Sony Handycam camera connected 
to a Cobalt Instruments computer. Data collected for each trial consisted of a track of the 
animal which included the latency to locate the platform, speed of swimming, and 
thigmotaxis. On the probe trial the tracking system also recorded the amount of time 
subjects spent in each of the four quadrants of the maze, as well as the number of times 
the animal’s path crossed over the previous platform location and its analogous location 
in each quadrant. 
 
Behavioral Testing 
 Animals received AF64A toxin infusions an average of four days before testing 
began in order to alter the cholinergic system consistent with early stages of AD. Daily 
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injections of donepezil or saline were administered 20 minutes prior to start of testing, 
while galanin or ACSF was centrally infused 5 minutes before testing began. Subjects 
were then taken individually from the colony room to a dedicated testing room containing 
the water maze, a computer desk, a table with the heating cage, and large geometric 
shapes positioned on each of the four walls, all serving as distal spatial cues. The rat was 
placed into the maze at one of three randomized locations, in the center of a quadrant that 
did not contain the escape platform (non-target quadrant). The rat was allowed to swim in 
the maze until it reached the hidden platform and placed its forepaws on the platform. If 
after 60 seconds the animal did not locate the hidden platform, it was guided to the 
platform by the experimenter. The rat was given 20 seconds on the platform to orient to 
distal spatial cues and was then placed under a heat lamp for a total of 30 seconds 
between trials. Three additional trials were conducted in an identical fashion, for a total 
of four training trials per day. Following the fourth trial, the animal was dried and then 
returned to its home cage. The training trials for the hidden platform were conducted until 
control subjects reached a latency criterion of less than 20 seconds for experiment 1 and 
less than 13 seconds for experiment 2. A more stringent criterion was set for experiment 
2 in order to ensure lesion animals had sufficient opportunity to learn the task. A probe 
trial was conducted five hours following achievement of this criterion. For probe trials, 
the rat was placed in the maze in the same fashion as during training, but the escape 
platform was absent. The single probe trial was 60 seconds in duration, after which the 
rat was dried and returned to its home cage.  
 The day after completion of the probe trial, a visible platform training protocol 
was used. A visible platform that extends above the surface of the water (intra-maze cue) 
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was placed into the maze instead of the hidden platform. Five trials were conducted for 
each animal in the same fashion as during the hidden platform training, with the 
exception that the platform location was changed on each trial. Visible platform training 
was conducted in order to detect any deficits in visual ability and motor function. Thirty 
minutes following completion of the last visible training trial, animals were humanely 
euthanized.   
 
Tissue Collection 
 Animals were humanely euthanized via carbon dioxide asphyxiation and half 
were transcardially perfused while the other half were immediately decapitated for rapid 
removal of the brain. Transcardiac perfusions involved perfusing saline through the 
vascular system via the left ventricle followed by perfusion of 8% paraformaldehyde to 
fix the tissue. Brains were then removed and placed in 8% paraformaldehyde at 4° C for 
48 hours followed by 24 hours in a 30% sucrose solution in PBS (phosphate-buffered 
saline). Finally, brains were placed in 5% sucrose in PBS until immunohistochemistry 
experiments. For rats that did not receive transcardiac perfusions, brains were quickly 
removed and cortex, hippocampi, and cerebellum were dissected out and flash frozen in 
dry ice. The dissected tissue was stored at -80° C until western blotting experiments.  
 
SDS-PAGE (Western Blots) 
 A total of twenty-four animals were randomly selected for the SDS-PAGE 
experiments which were only conducted with subjects from experiment 2. Tissue was 
homogenized in a non-denaturing lysis buffer consisting of 1X RIPA buffer (Cell 
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Signaling; 20 mM Tris-HCL pH 7.5, 150 mM NaCL, 1 mM Na2 EDTA, 1 mM EGTA, 
1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerophosphate, 1 mM Na3VO4, and 1 µg/ml leupeptin), 1 mM DTT, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 20 µg/ml aprotinin and 0.1% sodium dodecyl 
sulfate (SDS). Lysates were centrifuged at 15,000 x g for 15 minutes at 4°C, the 
supernatant was collected, and a protein assay to determine concentration was performed 
using the biciconinic acid method (BCA, Pierce, Rockford, IL). Samples (20 µg) were 
separated on 10% SDS-PAGE gels according to the method of Laemmli (1970). Proteins 
were then electro-transferred to nitropure 45 micron nitrocellulose membranes which 
were blocked in 5% milk in Tris-buffered saline 0.05% Tween (TBST) and sodium azide 
overnight.  
 Individual membranes were incubated with rabbit anti-VAChT (vesicular ACh 
transporter) antibody (1:750; Sigma-Aldrich, St. Louis, MO) or rabbit anti-β-actin 
antibody as control (1:1000; Sigma-Aldrich, St. Louis, MO) in TBST-5% milk plus 
sodium azide for 2 hours at room temperature. Detection of specific binding was 
performed by incubation with HRP-conjugated secondary antibodies (1:5000, Vector) for 
1 hour at room temperature. Specific signals were detected with Super Signal West Pico 
Chemiluminescent Substrate (Pierce, Rockford, IL) and images were then scanned for 
densitometry, using BioSpectrum Imaging System (UVP, Upland, CA) and average 
intensity was obtained for each sample using ImageJ software (National Institutes of 
Health).  
 
 
 44 
 
Immunohistochemistry 
 Twenty-three animals, all from experiment 2, were dedicated to 
immunohistochemistry experiments. Whole brains were sectioned at a thickness of 20µm 
on a cryostat and sections were stored at 4° C in PBS until the immunohistochemistry 
experiments. In order to verify correct cannula placement, sections were examined to see 
if cannulae terminated in the lateral ventricles. Animals whose cannulae did not terminate 
in the lateral ventricle were removed from the analyses. Sections were placed in plastic 
wells and remained free floating until the completion of the immunohistochemistry 
procedure. Sections were initially blocked for 45 minutes in a blocking solution 
containing 5% normal goat serum (NGS), 0.05% Tween, and PBS. Sections were then 
incubated overnight at room temperature in primary antibody solution containing 5% 
NGS, 0.3% Tween, 0.05% sodium azide, and primary polyclonal antibody raised in 
rabbit directed against the VAChT (1:750 dilution). All wells were then rinsed five times 
for five minutes each in an excess of wash solution (PBS, 0.2% NGS, and 0.05% Tween) 
with gentle rotation. Following the washes, sections underwent a procedure for labeling 
with 3, 3’ diaminobenzidine (DAB). Sections were incubated for 45 minutes in a 
biotinylated secondary antibody solution containing 5% NGS, PBS, and biotinylated 
secondary antibody (1:500 dilution; Elite Vectastain ABC kit, Burlingame, CA). 
Following five washes, sections were washed for 15 minutes in a hydrogen peroxide 
solution (3% hydrogen peroxide, 1% sodium azide, and wash solution) to eliminate non-
specific binding and then washed three more times. Sections were then incubated for 45 
minutes with ABC reaction in order to amplify the signal (Elite Vectastain ABC kit, 
Burlingame, CA) followed by another five washes. Finally, syringe-filtered DAB was 
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placed into the wells while the sections were free-floating for four minutes and then 
washed away using wash solution. Sections were then mounted onto slides for imaging 
under the microscope. 
 
Cell Counting 
 To determine the extent of cholinergic neuron loss in subjects from all groups 
administered the AF64A or sham lesion, slides were examined at an objective of 10X or 
20X using a Zeiss Axioskop II Plus microscope (Carl Zeiss MicroImaging, Inc, 
Thornwood, NY). Cell counts of VAChT-positive neurons within the basal forebrain and 
hippocampus were performed in a consistent manner across sections and groups. A 
minimum of six sections per animal with three to four animals per group was utilized to 
determine relative cholinergic abundance expressed as a percent of the sham controls. 
 
Statistical Analysis 
   Hidden platform training data were analyzed using the SPSS statistical software 
package by a repeated measures analysis of variance (ANOVA). Visible platform training 
and probe trial data were analyzed by one-way ANOVA. Western Blot densitometry and 
cell count data were also analyzed by one-way ANOVA. Tukey post-hoc comparisons of 
treatment groups were performed following a significant ANOVA. 
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CHAPTER 4 
RESULTS 
Experiment 1 
Morris Water Maze 
 An analysis of each group’s latency to reach the hidden platform in the 
Morris water maze revealed no significant differences among the groups (F3,124 = 0.208, 
p=.891; see figure 1A). Similarly, there were no significant differences among the groups 
in latency to find the visible platform (F3,131 = 1.197, p=0.314; see figure 1A). Speed of 
swimming was analyzed to investigate any differences in motoric ability among the 
groups. No significant differences were found among the groups with regard to swim 
speed during hidden training (F3,124 = 0.975, p=.407; see figure 1B) or visible training 
(F3,131 = 1.731, p=0.164; see figure 1B). Thigmotaxis, a measurement of how much time 
subjects spent around the outer perimeter of the maze, is typically used as a measure of 
anxiety. During hidden platform training, no significant differences were observed among 
the groups in thigmotaxis (F3,124 = 0.173, p=.915; see figure 1C). However, during visible 
platform training, significant differences were observed in thigmotaxis (F3,131 = 3.114, 
p<.05; Tukey post-hocs revealed that the donepezil-galanin group had significantly 
higher thigmotaxis than the saline-ACSF group,  p<.05; see figure 1C).  
 Following hidden platform training, the platform was removed and a probe trial 
was conducted to assess spatial learning (see figure 1D). A lack of a significant probe 
trial indicates a group did not learn the spatial location of the platform. Subjects in the 
saline-ACSF group spent significantly more time in the target quadrant versus each of the 
three non-target quadrants indicating a selective preference for the target location (F3,32 = 
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27.912, p<.01; Tukey post-hoc comparisons of target quadrant versus all non-target 
quadrants, p<.01). Rats administered donepezil and ACSF also displayed a significant 
search (F3,24 = 11.834, p<.01; Tukey post-hoc comparisons of target versus all non-target 
quadrants, p<.01). Animals that received saline and galanin did not show a selective 
search as not all non-target quadrants were significant versus the target (F3,28 = 5.759, 
p<.01; Tukey post-hocs revealed target was only significant versus quadrant 1, p<.01, 
and non-significant versus quadrants 2 and 3, p>.05) which is consistent with previous 
studies with galanin. Interestingly, in the group given donepezil and galanin, rats did not 
show a preference for the target quadrant (F3,28 = 2.350, p=.094).  
 
Experiment 2 
 
Morris Water Maze 
 
 Administration of the cholinergic neurotoxin alone or in combination with galanin 
and/or donepezil did not affect the animals’ latencies to find the hidden platform in the 
Morris water maze as is evidenced by the observation of no significant differences among 
the groups (F4,167 = 0.555, p=.696; see figure 2A). Interestingly, during visible platform 
training there was a significant difference in latency to reach the platform (F4,157 = 2.769, 
p<.05; Tukey post-hocs revealed that the lesion plus donepezil and galanin led to a 
significantly higher latency to reach the visible platform as compared to sham controls, 
p<.05; see figure 2A). No swim speed differences were observed in either hidden training 
(F4,167 = 2.181, p=.073) or visible platform training (F4,157 = 0.521, p=.721) among the 
groups (see figure 2B). When thigmotaxis was analyzed, a significant difference was 
found among the groups during hidden platform training (F4,167 = 2.760, p<.05; Tukey 
post-hocs showed the lesion plus donepezil and galanin produced significantly higher  
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Figure 1. Water maze performance in experiment 1 following donepezil and/or galanin 
administration. (A) Latency for hidden and visible platform training. No significant 
differences were found among treatments during either condition (p>.05). (B) No swim 
speed differences were detected among groups in either hidden or visible platform 
training (p>.05). (C) An examination of time spent around the outer perimeter of the 
maze revealed a significant difference in thigmotaxis during visible platform training in 
the donepezil-galanin group (p<.05) versus controls but no differences during hidden 
training. (D) Probe trial data show that only saline controls (p<.01) and donepezil-
administered animals (p<.01) spent significantly more time in the target quadrant versus 
each non-target quadrant indicative of a selective search. Groups administered galanin or 
donepezil and galanin did not display a selective search (p>.05). 
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thigmotaxis as compared to the sham controls, p<.05; see figure 2C). Similarly, during 
visible platform training significant differences were found among treatments (F4,157 = 
3.603, p<.01; Tukey post-hocs showed no significant differences compared to sham 
controls; however, the lesion plus donepezil and galanin produced significantly higher 
thigmotaxis as compared to the lesion group, the lesion plus donepezil, and the lesion 
plus galanin, ps<.05; see figure 2C).  
 Figure 2D depicts probe trial performance among the groups administered either 
AF64A or a sham lesion. Sham controls demonstrated a selective search as is evidenced 
by their significant probe trial (F3,32 = 59.444, p<.01; Tukey post-hoc comparisons of 
target versus all non-target quadrants, p<.01). Animals administered the lesion alone also 
showed a selective probe trial (F3,32 = 13.231, p<.01; Tukey post-hoc comparisons of 
target versus all non-target quadrants, p<.01). Surprisingly, rats infused with galanin 
following the lesion demonstrated a significant search as well (F3,28 = 38.027, p<.01; 
Tukey post-hoc comparisons of target versus all non-target quadrants, p<.01). Equally 
surprising was that the lesion plus donepezil and galanin group also exhibited a 
significant search on the probe trial (F3,32 = 44.361, p<.01; Tukey post-hoc comparisons 
of target versus non-target quadrants, p<.01). Interestingly, the group administered 
donepezil and ACSF following the lesion did not display a selective search during the 
probe trial (F3,28 = 5.345, p<.01; Tukey post-hocs revealed target was only significant 
versus quadrant 3, p<.01, and non-significant versus quadrants 1 and 2, p>.05).  
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Figure 2. Water maze performance in experiment 2 following a lesion and combinations 
of donepezil and galanin. (A) No differences were observed during hidden platform 
training although the lesion plus donepezil and galanin group displayed a significantly 
increased latency to find the visible platform (p<.05) versus sham controls. (B) No 
significant differences in swim speed were observed in either hidden or visible platform 
training (p>.05). (C) A significantly increased thigmotaxis was observed in the lesion 
plus donepezil and galanin group during hidden platform training (p<.05) versus sham 
controls and during visible platform training (p<.05) versus lesion, lesion plus donepezil, 
and lesion plus galanin groups but not sham controls. (D) Probe trial data indicate that 
sham controls (p<.01), lesion (p<.01), lesion plus galanin (p<.01), and lesion plus 
donepezil and galanin (p<.01) groups all spent significantly more time in the target 
quadrant versus each non-target quadrant. However, animals administered the lesion plus 
donepezil did not display a selective search indicating they did not learn the location of 
the platform (analysis of target versus non-target quadrants, p>.05).  
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Western Blotting 
  Western Blots were analyzed for image intensity and statistics were performed to 
examine differences among treatments. Representative blots of frontal cortex are shown 
in figure 3A. While there are indications of differences among groups, no significant 
differences among treatments were observed in protein levels of VAChT in the cortex 
(F4,31 = 1.637, p=.190; see figure 3A). A representative blot for the hippocampus is shown 
in figure 3B. Similar to cortex samples, although differences exist among treatments, no 
significant differences were found among groups in the hippocampus (F4,35 = 1.435, 
p=.243; see figure 3B).  
Cell Counts 
 Cell counts performed under light microscopy of DAB-stained tissue were done 
in the left and right basal forebrain region and left and right hippocampi to assess the 
number of cholinergic neurons. A significant difference was observed among the groups 
in the total number of VAChT-positive cells counted in the left and right basal forebrain 
(F4,203 = 3.464, p<.01; Tukey post-hocs revealed that the lesion plus galanin group had 
significantly fewer cholinergic-positive neurons in the basal forebrain as compared to 
sham controls, p<.05; see figure 4D). The lesion alone group displayed a non-significant 
trend toward a loss of cholinergic cells as compared to sham controls, however it did not 
reach significance, p=.095. Representative images of basal forebrain for sham controls, 
lesion, and lesion plus galanin groups are depicted in figure 4 (A, B, and C, respectively). 
Images for lesion plus donepezil and lesion plus donepezil and galanin groups are not 
shown due to the lack of significant differences between these groups and controls. Cell 
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counts performed in the hippocampus revealed no significant differences among 
treatments (F4,74 = 0.613, p=.655; data not shown).  
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Figure 3. Western Blot analyses. (A) Representative blots of samples from the frontal 
cortex along with the relative VAChT protein levels in each group compared to sham 
controls. Analyses of Western Blot densitometry revealed no significant differences 
among the groups (p>.05). (B) Representative blots of hippocampal samples along with 
the relative protein levels of VAChT compared to sham controls. No significant 
differences were observed among the groups (p>.05). S: sham controls; L: lesion; L + D: 
lesion + donepezil; L + G: lesion + galanin; L + D + G: lesion + donepezil + galanin.  
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Figure 4. Immunohistochemical cell counts within DAB-stained basal forebrain sections. 
(A) Representative image of a sham control brain. (B) Representative image of a lesion 
animal. (C) Representative image of a rat from the lesion plus galanin group. (D) An 
analysis of cell counts performed within the basal forebrain revealed that the lesion plus 
galanin group had significantly fewer VAChT-positive cells than sham controls (p<.01). 
All images were obtained at a 10X magnification.  
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CHAPTER 5 
SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS 
Discussion of Results 
 In the above studies we investigated the interaction of galanin and the 
cholinergic system with particular relevance to AD. Here we present the first behavioral 
evidence that the galanin-induced learning and memory impairment is likely not related 
to galanin modulating cholinergic signaling. Experiment 1 demonstrated that the 
previously observed deficit in spatial learning and memory due to galanin was not 
rescued or even modified by the administration of the AChE inhibitor donepezil. Several 
previous investigations have made a case for the impairments produced by galanin being 
driven by altering cholinergic tone (Melander et al., 1985; Fisone et al., 1987; Dutar et 
al., 1989; Mufson et al., 1998). This connection has also been used extensively to support 
the models of galanin overexpression in AD.  If the galanin-induced alteration of 
cholinergic signaling were in part responsible for its learning and memory deficits, the 
increase in cholinergic tone produced by donepezil should have altered and/or rescued the 
galanin-induced impairment. 
 In a recent study investigating the mechanisms responsible for the galanin 
learning deficit, it was found that galanin significantly reduced CREB phosphorylation 
(Kinney et al., 2009). Further, another investigation found that the administration of 
forskolin (an AC activator) was able to rescue the galanin-induced deficit (Kinney et. al. 
2003), providing further support that the spatial learning and memory deficits due to 
galanin may be mediated by its inhibition of AC activity and downstream 
phosphorylation of CREB.  Taken together, these data suggest that the investigation of 
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galanin deficits should focus more specifically on the intracellular signaling cascades 
modulated by galanin. However, the possibility still remains that the cholinergic cell loss 
and overexpression of galanin observed in AD result in a completely different scenario.  
 In order to examine the relationship between cholinergic cell loss similar to what 
is observed in AD and increased galanin levels, a cholinergic neurotoxin was centrally 
administered in experiment 2. When the interactions of donepezil and galanin were 
examined in a compromised cholinergic system, a completely different behavioral profile 
emerged. Most notably, the galanin-induced deficit, which has been well characterized in 
tasks of spatial learning and memory, was absent following the cholinergic lesion. In 
addition, donepezil administration following the lesion produced a deficit in the probe 
trial indicating these animals did not learn the spatial location of the platform. This result 
was somewhat surprising as the majority of the literature suggests that increasing 
cholinergic tone is beneficial to an organism. Importantly, co-administration of donepezil 
and galanin following the cholinergic lesion did not produce a learning and memory 
impairment even though higher thigmotaxis was seen throughout training in this group. 
Further, a deficit in latency to reach the visible platform was observed in these animals 
which can largely be accounted for by the increase in thigmotaxis observed during visible 
training. Because this group did not show any impairment in hidden platform training or 
the probe trial, this visible platform deficit is not likely due to any visuomotor 
impairments. Interestingly, animals co-administered donepezil and galanin in experiment 
1 also displayed increased thigmotaxis during visible platform training suggesting an 
anxiety phenotype may be present following co-administration of these compounds. 
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Future studies may be able to clarify any anxiogenic effects related to the interaction of 
galanin and donepezil.  
In the group administered a cholinergic lesion followed by saline and ACSF, no 
spatial learning and memory deficit was detected. Although this result was also 
unexpected, the data on spatial learning and memory following a cholinergic lesion are 
fairly inconsistent (Walsh et al., 1984; Lamberty et al., 1992; Nakamura et al., 1992; 
Opello et al., 1993; Dornan et al., 1996; Bizon et al., 2003; Frick et al., 2004; Dashniani 
et al., 2009). Whether or not a learning deficit is observed is likely tied to the extent of 
the cholinergic lesion and the particular neurotoxin employed. The unilateral cholinergic 
lesion administered in the current study was selected to induce mild damage to the basal 
forebrain, in an effort to mimic early or even preclinical AD. Thus, because our 
cholinergic insult was relatively small, the spatial learning task utilized may not have 
been sensitive enough to detect any behavioral changes due to the lesion. However, it is 
clear the lesion itself did have a physiological and behavioral impact as the effects of 
galanin and donepezil become radically different following the lesion versus in a normal, 
non-lesioned animal. Further, although not significant, there was a marked reduction in 
the amount of cholinergic-positive cells in the basal forebrain region of lesioned animals. 
The results from the Western Blot and immunohistochemistry (IHC) experiments 
are a little less clear. Although disagreements exist on the accuracy of  quantitative IHC 
techniques, the IHC experiments disclose useful and interesting information regarding 
neurobiological changes. Based on our data, there is a significant reduction in the amount 
of VAChT-positive cells in the basal forebrain region in animals administered the lesion 
plus galanin as compared to sham controls. This finding is contrary to what we expected 
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given the trophic effects that have been observed following galanin administration in 
vitro (Zini et al., 1993; Holmes et al., 2000; O’Meara et al., 2000; Mahoney et al., 2003; 
Elliot-Hunt et al., 2007). Further, because galanin administration following the lesion did 
not produce a learning and memory deficit in the water maze, this significant reduction in 
cholinergic-positive cells is even more surprising. The possibility exists that although 
galanin may not exhibit any neuroprotective qualities in vivo, its effects in a 
compromised cholinergic system are different than in a normal, non-lesioned animal. 
More data related to the in vivo effects of galanin in animal models relevant to the 
specific disease state may be necessary to clarify this galanin-induced change.  
There is also a non-significant trend (p=.095) towards a reduction in cholinergic 
cells in lesioned animals. Although this reduction did not reach significance in this group, 
it is clear the lesion did alter the amount of VAChT-positive cells in the basal forebrain. 
Interestingly, in the lesion plus donepezil and lesion plus donepezil and galanin groups, 
there is very little change in the amount of cholinergic neurons as compared to sham 
controls. Whether this lack of a reduction in cholinergic cells in these groups reflects any 
neuroprotective properties of donepezil is difficult to determine with the data at hand. 
However, previous studies have discovered possible neuroprotective effects of donepezil 
(Takada-Takatori et al., 2006; Akasofu et al., 2008), raising the possibility that daily 
donepezil administration may have negated the effects of the lesion in the current study. 
Interestingly, impairments in water maze learning were observed in the group 
administered donepezil following the lesion. These results suggest compensatory changes 
following the lesion in combination with donepezil administration may have disrupted 
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spatial memory. Further possibilities regarding the behavioral deficit in this group are 
outlined below.  
An analysis of the densitometry of the Western blots revealed no significant 
differences among the groups in either the cortex or the hippocampus. Interestingly 
however, the trends in the VAChT protein levels in the cortex seem to mirror the group 
differences observed following the IHC cell counts. The consistency observed between 
procedures in the differences among groups reinforces the validity of the findings. 
Further, although there is a large amount of variability within each group, clear trends are 
observable in the hippocampus as well. It is interesting to note that these trends tend to be 
opposed to the data from the Western blot cortex samples and the IHC basal forebrain 
cell counts. Spatial learning and memory in the Morris water maze is a hippocampally-
dependent task. Therefore, the shift in VAChT protein levels in the hippocampus in some 
of these groups could potentially account for why a deficit is observed in the lesion plus 
donepezil group while none is found in the lesion plus galanin group. Specifically, the 
Western data indicate that the lesion plus donepezil group has lower levels of VAChT 
protein in the hippocampus than the lesion and lesion plus galanin groups. This difference 
may play a role in the lesion plus donepezil group deficit, as further outlined below. The 
large variability observed within each group precludes the discovery of any significant 
differences among these groups, and a replication of these findings may be necessary 
before any definitive conclusions can be reached regarding the neurobiological effects of 
donepezil and/or galanin following a lesion. 
 The data from the above experiments indicate an interesting shift in the effects of 
galanin as well as the interaction of donepezil and galanin. In experiment 1, donepezil 
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alone did not alter performance while galanin impaired spatial learning and memory 
consistent with previous investigations. Interestingly, the galanin deficit was still present 
when donepezil was co-administered indicating the galanin learning impairment is likely 
not related to the suppression of cholinergic signaling. However, in the presence of a 
cholinergic lesion these effects were inverted. Following perturbation of the cholinergic 
system as in AD, the same dose of donepezil produced a spatial learning impairment 
while the same concentration of galanin (from the same batch) or co-administration of 
galanin and donepezil did not lead to a learning impairment. Even more compelling is 
that the cholinergic lesion alone was insufficient to impair learning and memory in the 
water maze. These data suggest that there are differential effects of both galanin and 
donepezil depending on the level of cholinergic tone. Further, it is also interesting to note 
that while the galanin deficit does not appear to be tied directly to the modulation of 
ACh, following the reduction of cholinergic tone as in AD, galanin does not produce an 
impairment. In addition, although administration of donepezil following the lesion 
impaired water maze performance, when galanin was co-administered with donepezil, 
this donepezil-induced deficit vanished. These data suggest that galanin may have a 
beneficial role in a compromised cholinergic system similar to what is observed in AD. 
These findings also support a more detailed investigation of galanin activity in specific 
disease state models as opposed to previous investigations of exogenous galanin 
administered to normal subjects.  
The role of galanin in AD is currently unknown with many investigators 
suggesting it may be exacerbating cognitive symptoms while others support a potential 
trophic role for galanin in the disorder. Interestingly, galanin has been shown to protect 
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neurons from the toxic effects of Aβ (Ding et al., 2006; Cheng & Yu, 2010; Cui et al., 
2010) and has also recently been demonstrated to rescue Aβ-induced learning and 
memory deficits in the Morris water maze (Cheng & Yu, 2010). These studies suggest the 
overexpression of galanin may serve a protective role in AD in an attempt to counteract 
the neurotoxic effects of Aβ. In the current study when cholinergic functioning was 
altered, galanin may also display protective properties similar to what is seen following 
Aβ infusion. However, the histological data did not reveal any neuroprotective qualities 
of galanin, indicating the lack of a behavioral deficit may be unrelated to galanin’s 
trophic properties.  
The cholinergic lesion also altered the behavioral outcome of donepezil 
administration, producing a deficit where none was observed without the lesion. This 
finding suggests neurological changes due to the lesion, perhaps compensatory in nature, 
followed by the inhibition of AChE may have created a scenario where the increase in 
cholinergic tone impaired spatial learning. In fact, there are reports that also demonstrate 
spatial learning deficits due to increasing cholinergic tone (Bunce et al., 2004; Elvander 
et al., 2004; Sabolek et al., 2005), particularly in the retrieval of previously learned 
information (Rogers & Kesner, 2004). This retrieval deficit is especially relevant in our 
study considering donepezil administration following the cholinergic lesion impaired 
probe trial performance in the Morris water maze. However, further studies are necessary 
to confirm and elucidate the mechanisms driving this donepezil-induced change. In 
addition, no deficit was observed following co-administration of donepezil and galanin in 
rats with a compromised cholinergic system, suggesting whatever effect galanin has 
following a lesion is sufficient to rescue the donepezil-induced deficit. It is possible that 
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the increase in cholinergic tone caused by donepezil was reduced by galanin 
administration (Fisone et al., 1987; Dutar et al., 1989; Palazzi et al., 1991), which 
restored ACh levels to a level consistent with other groups and eliminated the donepezil-
induced deficit. Clearly, the interactions between galanin and the cholinergic system 
become more complex following a cholinergic lesion mimicking early AD and more data 
may be required before any definitive interpretations can be made.   
Regardless of whether or not galanin plays a neuroprotective role in AD, based on 
the findings from experiment 1, the behavioral deficits attributed to galanin are more 
likely due to its inhibition of CREB phosphorylation (Kinney et al., 2009) and not tied to 
suppression of cholinergic signaling. Further, it may be necessary to readdress the 
behavioral consequences of galanin’s modulation of cholinergic functioning, especially in 
early or preclinical AD when ACh levels begin to fall and cognitive deficits begin to 
arise. A potentially more relevant approach to galanin in AD may be to address the 
mechanisms responsible for its overexpression in AD.  This approach may provide 
valuable data regarding the mechanisms involved in the pathology of AD.  For example, 
several groups have argued that calcium alterations may be tied to both the 
neurofibrillary tangles and Aβ plaques observed in AD (McKee et al., 1990; Hardy & 
Higgins, 1992; Mattson et al., 1992; Murray et al., 1992; Querfurth & Selkoe, 1994; 
Green & Laferla, 2008; Lopez et al., 2008; Vale et al., 2010).  As the transcriptional 
regulation of galanin is on a calcium-dependent switch, specifically a CREB-dependent 
transcription factor (Zachariou et al., 2001), the overexpression of galanin may be tied to 
other pathological findings in AD. Changes in calcium levels consistently observed in 
AD (Peterson et al., 1985; Landfield et al., 1989; Thibault & Landfield, 1996; Raza et al., 
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2007; Thibault et al., 2007; Bezprozvanny and Mattson, 2008; Bojarski et al., 2008) 
could potentially lead to increased CREB activation and an upregulation of galanin. In 
addition, as galanin has demonstrated neuroprotection against calcium-induced damage 
(Palazzi et al., 1991; Mazarati et al., 2000; Arabadzisz et al., 2005; Mazarati et al., 2006; 
Endoh et al., 2008), these changes in calcium levels alone could lead to the 
overexpression of galanin in AD.  
The potential upregulation of galanin following calcium dysegulation raises the 
possibility of utilizing galanin as a marker in animal models and perhaps AD as well. If 
the overexpression of galanin observed in AD and animal models of AD (Baraka & 
ElGhotny, 2010) is due to changes in calcium levels, then measuring levels of galanin 
may prove fruitful in the detection of AD in vivo. The development of galanin receptor 
ligands for clinical use has proven challenging. Therefore, investigations of galanin in 
AD may be better served by examining levels of galanin as a marker for cell damage or 
cell loss due to calcium alterations.  
The role of galanin in inhibiting the evoked release of classical neurotransmitters 
and preventing neuronal hyperactivity has been well documented (Dutar et al., 1989; 
Pieribone et al., 1995; Kinney et al., 1998; Xu et al., 1998). However, galanin’s inhibition 
of CREB phosphorylation provides a possible alternative explanation for its potential 
neuroprotective properties in a damaged nervous system. By inhibiting AC and 
downstream phosphorylation of CREB, galanin may be conserving vital resources by 
halting the activation of several transcription factors. This reduction in transcription may 
allow a struggling nervous system to allocate resources where necessary without 
expending unwanted energy, which could be critical in a neurodegenerative disorder such 
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as AD. In the current study, galanin did not produce a spatial learning and memory 
impairment when administered to an animal with a compromised cholinergic system. 
This finding is unique as previous investigations with several learning and memory tasks 
have typically demonstrated learning impairments following galanin administration. 
Together with results from previous studies indicating galanin inhibits CREB 
phosphorylation (Kinney et al., 2009), these findings could potentially support a role for 
galanin in the preservation of a damaged nervous system in response to cellular insults as 
may be occurring in AD. 
The cognitive effects of galanin overexpression in AD are currently unknown 
while many investigators suggest galanin may be exacerbating cognitive deficits by 
suppressing cholinergic tone. The current study emphasizes that the spatial learning and 
memory impairments following galanin administration are likely distinct from 
cholinergic modulation. Previous work indicates perhaps more attention instead should 
be paid to galanin’s inhibition of CREB phosphorylation as a potential modulator of 
learning and memory (Kinney et al., 2003; Kinney et al., 2009). Further, the data suggest 
galanin administration may be beneficial for spatial learning in an animal model of AD 
mimicking cholinergic loss as well as in other studies following infusion of Aβ peptide 
(Cheng & Yu, 2010). Although more studies are necessary to elucidate any 
neuroprotective effects of galanin in vivo, our data argue for a reappraisal of the role of 
galanin in learning and memory as well as AD. These findings may also impact the utility 
of administering galanin receptor ligands both in AD as well as other neurodegenerative 
disorders. 
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